Friday, 13 March 2020

Lattice Biologics Is The Next Vaxil Bio

On February 27, we issued an alert on Vaxil Bio (VXL.V) (VXLLF) as the next big Coronavirus play hidden on the TSX Venture. Since then, VXL has risen to $0.26 from $0.08 and has hit as high as $0.34. We are issuing another alert on a Coronavirus play on the TSX Venture that is very similar in nature to VXL. Lattice Biologics Ltd. (LBL.V) (LBLTF) currently sits at $0.05 in afternoon trading, pulling back from $0.075 but still up 100% on the day. We think this is an opportune time to issue a buy alert as day traders who chased it higher are dumping at what we believe to be is the floor and the stock could fly next week. Stocks like Alpha Pro Tech (APT), Vaxart (VXRT), iBio (IBIO), NanoViricides (NNVC) and Co-Diagnostics (CODX), among others have all been trading upwards thanks to the Coronavirus outbreak and we think that TSX Venture plays like VXL have been overlooked. We are up to 869 followers on our ValueTrades blog despite not giving out a lot of alerts, a fact that we think is indicative of a successful, diligent and prudent stock picking history. You can follow us on Twitter @StockTradePicks. We have over 4,000 followers on Twitter.

Lattice Biologics has 93 million shares outstanding, comparable to VXL's 89 million so it has the potential to go on a similar run. LBL is a little bit different in that instead of a vaccine, it is working on a treatment to the principal cause of death of COVID-19. It released the following news today:


Lattice Biologics to Evaluate Anti-Inflammatory Stem Cell Therapy Treatment of COVID-19 Lung Disease

BELGRADE, Mont.

Lattice Biologics Ltd. (TSX-V: LBL) (OTCQB: LBLTF) (“Lattice Biologics” or the “Company”) today announced that it plans to evaluate its amniotic fluid concentrate, AmnioBoost, in patients with acute respiratory distress syndrome (ARDS) caused by coronavirus (COVID-19)
AmnioBoost has potential for use in the treatment of ARDS, which is the principal cause of death in COVID-19 infection.1 Mortality in COVID-19 infected patients with the inflammatory lung condition (ARDS) is reported to approach 50%, and is associated with older age, co-morbidities such as diabetes, higher disease severity, and elevated markers of inflammation.1 Current therapeutic interventions do not appear to improve in-hospital survival.1
AmnioBoost is believed to have immunomodulatory properties to counteract the inflammatory processes that are implicated in several diseases by down-regulating the production of pro-inflammatory cytokines, increasing production of anti-inflammatory cytokines, and enabling recruitment of naturally occurring anti-inflammatory cells to involved tissues.
Major anti-inflammatory cytokines found in AmnioBoost include: interleukin (IL)-1beta, IL-1ra, TNF-alpha, IL-6, IL-8, IL-16, CCL2, CXCL7, MIF, and GRO a/b/g. Specific cytokine receptors for IL-1, and tumor necrosis factor-alpha, function as proinflammatory cytokine inhibitors.
This is supported by recently published results from an investigator-initiated clinical study conducted in China which reported that allogeneic mesenchymal stem cells (MSCs) cured or significantly improved functional outcomes in all seven treated patients with severe COVID-19 pneumonia.2
AmnioBoost
AmnioBoost was originally developed for chronic adult inflammatory conditions such as osteoarthritis, but has found multiple uses in the treatment of bone and cartilage repair, as well as soft tissue repair. It is an investigational therapy comprising concentrated allogeneic MSCs and cytokines derived from amniotic fluid.
The amniotic fluid is donated from non-related, healthy mothers and recovered by caesarian section; the baby is not harmed in any way. Additionally, AmnioBoost has been injected in over 1,000 patients with no adverse events, and appears to be well tolerated.
References
1. Liu Y et al. Clinical features and progression of acute respiratory distress syndrome in coronavirus disease 2019. Medrxiv 2020; https://doi.org/10.1101/2020.02.17.20024166
2. Leng Z, et al. Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia[J]. Aging and Disease, 10.14336/AD.2020.0228
About Lattice Biologics Ltd.:
Lattice Biologics is traded on the TSX-V under the symbol: LBL. The Company is an emerging leader in the field of cellular therapies and tissue engineering, with a focus on dental indications.
Lattice Biologics develops and manufactures biologic products to domestic and international markets. The Company’s products are used in a variety of surgical applications.
Lattice Biologics maintains its headquarters, laboratory and manufacturing facilities in Belgrade, Montana as well as offices in Phoenix, Arizona. The facility includes ISO Class 1000 clean rooms, and specialized equipment capable of crafting traditional allografts and precision specialty allografts for various clinical applications. The Lattice Biologics team includes highly trained tissue bank specialists, surgical technicians, certified sterile processing and distribution technicians, and CNC operators who maintain the highest standards of aseptic technique throughout each step of the manufacturing process. From donor acceptance to the final packaging and distribution of finished allografts, Lattice is committed to maintaining the highest standards of allograft quality, innovation, and customer satisfaction.
Lattice Biologics maintains all necessary licensures to process and sell its tissue engineered products within the U.S. and internationally. This includes Certificates to Foreign Governments from the U.S. Food and Drug Administration (FDA) and registrations for multiple countries, which allow the export of bone, tendon, meniscus, ligament, soft tissue, and cartilage products outside of the U.S.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
CEO Guy Cook recently settled $1 million of debt for 20 million shares at $0.05. When the conversion took place, it was a 100% premium to the stock price. Now that may be why it pulled back a bit after the initial positive reaction. We think this represents an excellent buying opportunity as $0.05 is the floor. The CEO wouldn't convert the shares at that level if he thought they weren't worth at least that much.

Disclosure: We are long LBL.V


What's next for microcap stocks? TradeMiner identifies seasonal trends and market cycles, the Penny Stock Prophet and Microcap Millionaires finds the next big small cap plays in various industries while Addicted to Profits makes trades from a Canadian perspective.

There are also some good books available on microcap stocks and day trading such as:

Mastering Microcaps: Strategies, Trends, and Stock Selection (Bloomberg Professional Library)

The Little Black Book of Microcap Investing: Beat the Market with NASDAQ/AMEX Microcap Stocks, OTCBB Penny Stocks, and Pink Sheet Stocks

Microcap Magic: Why The Biggest Returns Are In Stocks You've Never Heard Of

How to Day Trade for a Living: A Beginner’s Guide to Trading Tools and Tactics, Money Management, Discipline and Trading Psychology

How to Day Trade: A Detailed Guide to Day Trading Strategies, Risk Management, and Trader Psychology

A Beginner's Guide to Day Trading Online (2nd edition)

Stock Investing for Beginners: Marijuana Stocks


Here are some other good stock market resources. This includes technical analysis and day trading, dividend stock investing, gold and commodities, sector rotation, options trading and microcap trading strategies:

The dividend stock report from dividendstocksonline.com

Posted by at